TVTXTravere Therapeutics, Inc.

$3B

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$47M+6.7% YoY

Gross Profit

$40M85.0% margin

Operating Income

-$19M-40.6% margin

Net Income

-$30M-64.8% margin

EPS (Diluted)

$-0.69

QoQ Revenue Growth

+5.2%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$605M

Total Liabilities

$384M

Stockholders' Equity

$221M

Cash & Equivalents

$62M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$47M	$44M	+6.7%
Gross Profit	$40M	$42M	-5.9%
Operating Income	-$19M	-$5M	-279.9%
Net Income	-$30M	-$7M	-305.9%

Revenue Segments

Bile Acid Products

$20M100%

TVTX Q4 2019 Earnings — Travere Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena